Skip to content
10-Q

Quarterly Report

REGEN BIOPHARMA, INC. RGBP RGBPP

0001641172-25-012619

← back to feed
Filed
May 28, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · May 21, 2025 21.55M sh
Current Liabilities Q2 2025 · Mar 31, 2025 $5.87M
Current Liabilities Q2 2025 · Sep 30, 2024 $5.38M
Total Liabilities Q2 2025 · Mar 31, 2025 $5.87M
Total Liabilities Q2 2025 · Sep 30, 2024 $5.38M
Current Assets Q2 2025 · Mar 31, 2025 $151.75K
Current Assets Q2 2025 · Sep 30, 2024 $143.35K
Total Assets Q2 2025 · Mar 31, 2025 $169.48K
Total Assets Q2 2025 · Sep 30, 2024 $161.08K
Shares Diluted Q2 2025 · Mar 31, 2024 4.11M sh
Shares Diluted Q2 2025 · Mar 31, 2024 3.6M sh
Operating Cash Flow restated Q2 2025 · Mar 31, 2024 −$371.66K
Stockholders Equity Q2 2025 · Mar 31, 2024 −$5.18M
Stockholders Equity restated Q2 2025 · Sep 30, 2023 −$5.1M
Eps Diluted Q2 2025 · Mar 31, 2024 −$0.03
Eps Diluted Q2 2025 · Mar 31, 2024 −$0.07
Eps Basic Q2 2025 · Mar 31, 2024 −$0.03
Eps Basic Q2 2025 · Mar 31, 2024 −$0.07
Rd Expense Q2 2025 · Mar 31, 2024 $40.13K
Rd Expense Q2 2025 · Mar 31, 2024 $87.66K
Net Income restated Q2 2025 · Mar 31, 2024 −$122.45K
Net Income restated Q2 2025 · Mar 31, 2024 −$267.39K
Operating Income Q2 2025 · Mar 31, 2024 −$101.07K
Operating Income restated Q2 2025 · Mar 31, 2024 −$223.85K
Revenue Q2 2025 · Mar 31, 2024 $59.06K
Revenue Q2 2025 · Mar 31, 2024 $118.13K